PR:000001168 PR 5-hydroxytryptamine receptor 2C GO:0023052 GO signaling MP:0003606 MP kidney failure 1 WIKI increased 10116 NCBI rat Activation, 5HT2c Molecular CL:0000540 CL neuron AOPWiki 2016-11-29T18:41:22 2017-09-16T10:14:52 Increased, Kidney Failure Population AOPWiki 2016-11-29T18:41:26 2019-01-16T08:57:09 N/A, Unknown Molecular CL:0000255 CL eukaryotic cell AOPWiki 2016-11-29T18:41:23 2017-09-16T10:14:15 AOPWiki 2016-11-29T18:41:35 2016-12-03T16:38:00 Not Specified Mixed Not Specified AOPWiki 2016-11-29T18:41:35 2016-12-03T16:38:00 Kidney toxicity induced by activation of 5HT2C Kevin Crofton <p>Kevin M. Crofton, croftonwork at outlook dot com</p> Open for adoption 1.0 <p>This is a proposed AOP that is based on simple correlational analyses between ToxCast high-throughput screening data and significant increased odds rations for adverse outcomes. This specific proposed AOP is based on results presented in Thomas RS, Black MB, Li L, Healy E, Chu TM, Bao W, Andersen ME, Wolfinger RD.A comprehensive statistical analysis of predicting in vivo hazard using high-throughput in vitro screening. Toxicol Sci. 2012 Aug;128(2):398-417. doi: 10.1093/toxsci/kfs159. Epub 2012 Apr 26. PMID: 22543276</p> <p>The main purpose of posting this proposed AOP that provides nothing more than a MIE and an adverse outcome is to generate input on whether there are any known biological key events that would link the MIE to the AO.</p> non-adjacent Low Low non-adjacent Low Low <p><em>Consider the following criteria (may include references to KE Relationship pages): 1. concordance of dose-response relationships; 2. temporal concordance among the key events and adverse effect; 3. strength, consistency, and specificity of association of adverse effect and initiating event; 4. biological plausibility, coherence, and consistency of the experimental evidence; 5. alternative mechanisms that logically present themselves and the extent to which they may distract from the postulated AOP. It should be noted that alternative mechanisms of action, if supported, require a separate AOP; 6. uncertainties, inconsistencies and data gaps. </em></p> <p>Thomas RS, Black MB, Li L, Healy E, Chu TM, Bao W, Andersen ME, Wolfinger RD.A comprehensive statistical analysis of predicting in vivo hazard using high-throughput in vitro screening. Toxicol Sci. 2012 Aug;128(2):398-417. doi: 10.1093/toxsci/kfs159. Epub 2012 Apr 26. PMID: 22543276</p> AOPWiki 2016-11-29T18:41:16 2023-04-29T16:02:55